The BioProcess Insider Expression Platform Dan Stanton

MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
This episode of our regular podcast Voices of Biotech  brings you an in-depth conversation with Jeffrey Whitford, vice president of sustainability and social business innovation at MilliporeSigma, the life sciences division of Merck KGaA.
Whitford speaks about the company’s interim and long-term sustainability initiatives and provides a detailed outline of how the firm intends to meet their goals. Additionally, the conversation develops to discuss how integral people are when it comes to sustainability.
He puts forward the idea that it is not about people meeting you where you are at in terms of sustainability, but more about ensuring that you meet people where they are at, to develop an understanding of why and how you are reaching this aim.
According to Whitford, education (both self and academia) is vital to creating an unbreakable chain for sustainability. He talks about the academic partnerships MilliporeSigma has and the goal of making this global. Furthermore, he closes the conversation by adding how we need to be prepared to sometimes live in a little bit of discomfort and embrace change to really help make a difference.
The latest episode can be found here or through the BioProcess Insider Expression Platform at, Spotify, Apple iTunes, Google podcasts, or wherever you get your podcasts.
 

Samsung Biologics' James Choi discusses the CDMO’s role in teaming up with Big Pharma to tackle sustainability in the biotech space. 
 
This episode of the Voices of Biotech – brought to you by the BioProcess Insider Expression Platform – brings you an interesting conversation with Choi about the commitment to a “greener” supply chain.
 
In July 2023, CEOs from Roche, GlaxoSmithKline (GSK), AstraZeneca, Novo Nordisk, Merck KGaA, Sanofi, and contract development manufacturing organization Samsung Biologics signed an open letter calling on suppliers to commit to climate and sustainability targets.
 
The healthcare industry contributes approximately 5% of global greenhouse gas emissions, 50% of which comes from supply chains. The letter said called on biopharma collaborators to speedily move towards a “greener, more efficient, and circular” process. Additionally, it urged suppliers to sign-up to a joint minimum climate and sustainability targets, based around fundamental commitments laid out by the same seven firms ahead of COP27 in November 2022.
 
Choi, executive vice president, chief marketing officer, and head of sales support and global public affairs at Samsung Biologics, speaks about the CDMO’s involvement in teaming up with Big Pharma players to reach specific sustainability goals by 2025 and beyond. He talks about the important role a service provider plays in being more sustainable, Samsung Biologics’ own sustainability measures at the firm, and how the coalition came to fruition.
 
On top of being part of a coalition to advance sustainability in the sector, Choi also talks in depth about the buildout of its facilities and the measures they have put in place to ensure the next plant is “greener than the one before.”
 
The latest episode can be found below or through the BioProcess Insider Expression Platform at, Spotify, Apple iTunes, Google podcasts, or wherever you get your podcasts.
 

The director of strategy and alliance management at Core Biogenesis discusses the advantages, challenges, and how plant-based processes contribute to sustainability in the biotech space.   
This episode of the Voices of Biotech – brought to you by the BioProcess Insider Expression Platform – brings you an exciting conversation with Quentin Vicard, strategy and alliance management at Core Biogenesis.  
In July 2022, Core Biogenesis bagged $10.5 million in a Series A funding round to build a plant-based bioproduction facility located in Strasbourg, France. The plant is dedicated to manufacturing growth factors and cytokines for the cell therapy space and cellular agricultural industry. 
Vicard speaks about the company’s technology platform that can express recombinant proteins from the seeds of a Camelina sativa oilseed plant. He talks in-depth about the benefits of using a plant-based process, the challenges that come with it, and the firm’s future goals. 
On top of cost benefits, less space required, and impressive scalability, Vicard tells our listeners how its plant-based process has less of an impact on the environment and why sustainability is at the core of Core Biogenesis. Additionally, the conversation touches on the regulatory challenges companies are faced with when using a method that differs from the norm.  

Joel Eichmann, the co-founder and managing director of Green Elephant Biotech, discusses sustainable single-use products, the importance of data, and how healthy people need a healthy planet
Eichmann speaks about the firm’s plant-based plastic single-use products and how it is contributing to making the world that little bit greener, despite being told a few years ago the company was ahead of its time. Additionally, the life cycle of the product is discussed, and the conversation evolves to talk about the ecosystem needed to recycle effectively.  
He goes on to bring up an important point about how drugs in the life sciences space are saving lives, however, to reap the full benefit of commercialized medicine, we need to have a healthy planet for the healthy people to live on.  

The co-CEO’s of the FemTech Association Asia discuss democratizing women’s health and the femtech investment opportunities in Asia.   
Davis said their goal is to, “provide a voice for [Asia] and help amplify the industry […]  Femtech is known for being delivered for a premium audience and we want to take this wider and make sure we have solutions that are available, accessible, and affordable for all women.”
In addition to increasing accessibility to healthcare for all women, the association is encouraging investment opportunities in FemTech. For instance, 14% of FemTech business are located in Asia, making this an impactful area for the industry and for women’s health. By promoting this industry in this location, the association is helping Asia position itself as a leader in FemTech.

The three founders of the CGT Circle discuss the importance of decentralized networking for women and why the network was created.
In the latest episode of Voices of Biotech, brought to you by the BioProcess Insider Expression Platform, editor of BioProcess Insider Mille Nelson sits down with the three founding members of the CGT Circle.
They discuss the demand for local community led networking, leading them to launch their platform which aims to create “decentralized networking” for women in the Life Sciences industry.
“Our aim is to facilitating networking and take the fear factor out of it,” says Kate Fynes, one of the CGT Circle founding members and CMC translation consultant at eXmoor Pharma Concepts Ltd.
This allows women at different stages of their careers to share experiences and support each other professionally and personally.
Running for only 5 months, the CGT Circle has gained over 700 members and events have taken place across America, London, and Paris, with the next event occurring in Nottingham, UK 27th July.